Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)

PHASE3CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Invasive Fungal InfectionsHematologic Malignancies
Interventions
DRUG

Posaconazole

200 mg three times daily by mouth up to 6 weeks (Days 1-42)

DRUG

ABLC

7.5 mg/kg of ABLC intravenously infused over 4-6 hours once per week, for up to 6 weeks (from Day 1 through Day 42)

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Enzon Pharmaceuticals, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER